Biotech company Genzyme celebrated the tenth anniversary of a life-saving treatment at its Oxford offices.

Patient groups and doctors joined Genzyme representatives at a ceremony at Oxford Business Park to mark the UK anniversary of Cerezyme, an enzyme replacement therapy for the rare genetic disorder Gaucher disease.

The disease can cause anaemia, fatigue, easy bruising and a tendency to bleed. An enlarged spleen and liver may also occur as well as bone pain and fractures.

Susan Lewis, of the Gauchers Association, gave a certificate marking the anniversary to Genzyme chairman and chief executive Henry Termeer, and doctors from the UK's specialist centres caring for patients with Gaucher's talked about the past decade of treatment.

Genzyme, a US company which employs 40 people in its Oxford subsidiary Genzyme Homecare, is under investigation by the Office of Fair Trading after it was accused of abusing its dominant position in the market.

Cerezyme is the only treatment for Gaucher's. Genzyme offers its own homecare treatments as well as supplying the drug.